PGEN logo

PGEN Precigen Inc

$8.54
$0.33
(4.02%)
Today
Closed $8.54
$0.00
(0.00%)
After Hours
68

Bullish Sentiment

How do you feel about PGEN?

Loading...
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
Zacks
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.
Zacks
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?
Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
Novo's real-world study finds that patients who increase their Ozempic to 2 mg have a lower observed MACE risk than those who switch to Mounjaro.
Zacks
uniQure Plunges on Additional Data From Huntington's Disease Study
QURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month data add uncertainty.
Zacks
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.
Zacks
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
Iovance hits a 52-week high after raising its 2026 revenue outlook to $410-$420 million on strong demand for its marketed therapies.
Zacks
Here's Why You Should Add URGN Stock to Your Portfolio Now
UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.
Zacks
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo
ABBV wins FDA approval for Juvmo, expanding its Parkinson's portfolio with a once-daily oral treatment and potential $5B-plus PD opportunity.
Zacks